NCT06258018View on ClinicalTrials.gov

Niraparib and Temozolomide in Patients Glioblastoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

86

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2027

Conditions

Glioma, Malignant

Interventions

DRUG

Temodal

given orally for 7 consecutive days, followed by 7 days OFF, in a cycle of 28 days

DRUG

Niraparib

given orally in continous

Trial Locations (1)

20089

Istituto clinico humanitas, Rozzano

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

Istituto Clinico Humanitas

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Armando Santoro, MD

OTHER